Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Algert Global LLC

Algert Global LLC boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 22.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 262,298 shares of the company’s stock after buying an additional 48,358 shares during the quarter. Algert Global LLC owned 0.05% of Elanco Animal Health worth $3,785,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ELAN. Vanguard Group Inc. increased its position in shares of Elanco Animal Health by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after purchasing an additional 467,196 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Elanco Animal Health by 4.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock valued at $360,425,000 after purchasing an additional 852,281 shares during the last quarter. Ancora Advisors LLC increased its position in shares of Elanco Animal Health by 1.4% in the 1st quarter. Ancora Advisors LLC now owns 10,641,194 shares of the company’s stock valued at $173,239,000 after purchasing an additional 143,326 shares during the last quarter. Magnetar Financial LLC increased its position in shares of Elanco Animal Health by 61.2% in the 2nd quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock valued at $120,298,000 after purchasing an additional 3,164,350 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Elanco Animal Health by 11.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,990,546 shares of the company’s stock valued at $86,444,000 after purchasing an additional 609,194 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael J. Harrington bought 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The stock was purchased at an average price of $14.85 per share, with a total value of $51,975.00. Following the purchase, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. The disclosure for this purchase can be found here. 0.57% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have commented on ELAN. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a research report on Thursday, September 19th. Barclays increased their price objective on shares of Elanco Animal Health from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Monday, September 23rd. Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Piper Sandler dropped their target price on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, July 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.43.

Elanco Animal Health Trading Up 2.5 %

NYSE ELAN opened at $14.68 on Tuesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. The firm’s fifty day moving average price is $14.09 and its 200 day moving average price is $15.06. The company has a market capitalization of $7.25 billion, a price-to-earnings ratio of -5.54, a price-to-earnings-growth ratio of 1.33 and a beta of 1.40. Elanco Animal Health Incorporated has a 12 month low of $8.52 and a 12 month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. Elanco Animal Health’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.18 EPS. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.